Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

(2020) Zunyou Wu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

An interactive web-based dashboard to track COVID-19 in real time

(2020) Ensheng Dong et al.   LANCET INFECTIOUS DISEASES

Semaglutide attenuates excessive exercise-induced myocardial injury through inhibiting oxidative stress and inflammation in rats

(2020) Qiang Li et al.   LIFE SCIENCES

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2

(2020) Renhong Yan et al.   SCIENCE

Cytokine storm intervention in the early stages of COVID-19 pneumonia

(2020) Xinjuan Sun et al.   CYTOKINE & GROWTH FACTOR REVIEWS

COVID-19 and diabetes: Can DPP4 inhibition play a role?

(2020) Gianluca Iacobellis   DIABETES RESEARCH AND CLINICAL PRACTICE

Diabetes is a risk factor for the progression and prognosis of COVID-19

(2020) Weina Guo et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

(2020) Wei-jie Guan et al.   EUROPEAN RESPIRATORY JOURNAL

Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease

(2020) Carmen Ciavarella et al.   MOLECULES

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France

(2020) François Montastruc et al.   THERAPIE

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19

(2020) Sebastiano Bruno Solerte et al.   ACTA DIABETOLOGICA

Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety

(2020) Saghir Akhtar et al.   JOURNAL OF DRUG TARGETING

Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?

(2020) Elena Carboni et al.   MEDICAL HYPOTHESES

Factors associated with COVID-19-related death using OpenSAFELY

(2020) Elizabeth J. Williamson et al.   NATURE

Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study

(2020) Emma Barron et al.   Lancet Diabetes & Endocrinology

Diabetes and Novel Coronavirus Infection: Implications for Treatment

(2020) David M. Williams et al.   Diabetes Therapy

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study

(2020) Sebastiano Bruno Solerte et al.   DIABETES CARE

Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?

(2020) Niki Katsiki et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

The active GLP-1 analogue liraglutide alleviates H9N2 influenza virus-induced acute lung injury in mice

(2020) Yu Bai et al.   MICROBIAL PATHOGENESIS

Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis

(2019) H. Hussein et al.   DIABETIC MEDICINE

Rosiglitazone, a Ligand to PPARγ, Improves Blood Pressure and Vascular Function through Renin-Angiotensin System Regulation

(2019) María Sánchez-Aguilar et al.   PPAR Research

LIRAGLUTIDE AND SEMAGLUTIDE ATTENUATE INFLAMMATORY CYTOKINES INTERFERON-GAMMA, TUMOR NECROSIS FACTOR-ALPHA, AND INTERLEUKIN-6: POSSIBLE MECHANISM OF DECREASING CARDIOVASCULAR RISK IN DIABETES MELLITUS

(2019) Stanley Andrew Tan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Diabetes drugs and stroke risk: Intensive versus conventional glucose‐lowering strategies, and implications of recent cardiovascular outcome trials

(2019) Soo Lim et al.   DIABETES OBESITY & METABOLISM

Glucagon-like peptide 1 in health and disease

(2018) Andreas Andersen et al.   Nature Reviews Endocrinology

Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?

(2018) Yixing Li et al.   Current Cardiology Reports

Liraglutide Enhances the Activity of the ACE-2/Ang(1–7)/Mas Receptor Pathway in Lungs of Male Pups from Food-Restricted Mothers and Prevents the Reduction of SP-A

(2018) J. Fandiño et al.   International Journal of Endocrinology

Efficacy and safety of sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes: a systematic review and network meta-analysis study protocol

(2018) Humaira Hussein et al.   BMJ Open

Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments

(2015) Francesco Zaccardi et al.   ANNALS OF INTERNAL MEDICINE

Preservation of Glucagon-Like Peptide-1 Level Attenuates Angiotensin II-Induced Tissue Fibrosis by Altering AT1/AT2 Receptor Expression and Angiotensin-Converting Enzyme 2 Activity in Rat Heart

(2015) Li-Hui Zhang et al.   CARDIOVASCULAR DRUGS AND THERAPY

Activation of the GLP-1 Receptor by Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats

(2015) Marina Romaní-Pérez et al.   ENDOCRINOLOGY

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

(2013) T A Wadden et al.   INTERNATIONAL JOURNAL OF OBESITY

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

(2013) V. Stalin Raj et al.   NATURE